Declozindol

ID: declozindol

Aliases: identity unresolved; possible mazindol-like scaffold

Type: compound

Route/form: oral or route depends on studied product

Status: unresolved

Evidence level: unresolved

Best data tier: unresolved identity; adjacent early human

Support scope: human, non-human/mechanistic

Source types: early_human, medicinal_chemistry

Linked sources: 2

Broad outcomes: Brain / mood / sleep

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• norepinephrine transporter inhibition
• orexin-2 receptor agonism

Optimization domains

• wakefulness
• ADHD
• orexin

Research basis

• A combined NET/OX2R wakefulness profile would be pharmacologically interesting if identity is confirmed.
• Orexin-2 agonism is an active narcolepsy development field.

Limits, risks, and missing evidence

• No clear primary source for Declozindol identity was found in this seed pass.

Risk flags

• unresolved identity
• stimulant

Linked papers, labels, and reviews

1. Discovery of the first selective, nonpeptidic orexin 2 receptor agonists
   medicinal_chemistry / pubmed_orexin2_agonists_2015
   OX2R agonist field context.
2. Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype
   early_human / pubmed_danavorexton_2022
   Human and mouse evidence for OX2R agonism.